{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:24:02Z","timestamp":1773473042626,"version":"3.50.1"},"reference-count":27,"publisher":"BMJ","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2012,3,30]]},"published-print":{"date-parts":[[2012]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim was to examine statin discontinuation rates in a cohort of elderly Australians with newly diagnosed cancer using population-based secondary health data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>New South Wales, the largest jurisdiction in Australia. The Pharmaceutical Benefits and Repatriation Pharmaceutical Benefits Schemes are national programmes subsidising prescription drugs to the Australian population and Australian Government Department of Veterans' Affairs clients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The cohort comprised 1731 cancer patients aged \u226565\u2005years with evidence of statin use in the 90\u2005days prior to diagnosis. They were matched to 3462 non-cancer patients prescribed statins in the same period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measure<\/jats:title>\n                    <jats:p>The authors compared statin discontinuation rates up to 4\u2005years post-diagnosis and examined the factors associated with statin discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of cancer patients discontinuing statin therapy at 4\u2005years (27%) was comparable to the comparison cohort; however, significantly higher proportions of the cancer cohort discontinued statins than the comparison cohort at 3, 6 and 12\u2005months of follow-up (9.7% vs 7.4% at 12\u2005months, respectively). More than 30% of cancer patients who died were dispensed statins within 30\u2005days of death. Discontinuation of statin therapy in cancer patients was associated with regionalised and distant disease spread at diagnosis (p&lt;0.001), older age (p=0.006), upper gastrointestinal organs and liver cancer (aHR 2.95, 95% CI 1.92 to 4.53) and cancer of the lung, bronchus and trachea (aHR 1.99, 95% CI 1.32 to 3.00) and poorer survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medications should be rationalised at the time of a cancer diagnosis, especially in the setting of a poor prognosis. At least for some patients in our cohort, statin therapy may be inappropriately continued which adds unnecessarily to therapeutic burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2012-000880","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T20:42:07Z","timestamp":1337632927000},"page":"e000880","source":"Crossref","is-referenced-by-count":39,"title":["Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage"],"prefix":"10.1136","volume":"2","author":[{"given":"Efty P","family":"Stavrou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"key":"2025120519022086000_2.3.e000880.1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483887"},{"key":"2025120519022086000_2.3.e000880.2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/082585970602200405","article-title":"Physician practice in the discontinuation of statins among patients with advanced lung cancer","volume":"22","author":"Tanvetyanon","year":"2006","journal-title":"J Palliat Care"},{"key":"2025120519022086000_2.3.e000880.3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/082585970702300310","article-title":"The broader implications of managing statins at the end of life","volume":"23","author":"Stevenson","year":"2007","journal-title":"J Palliat Care"},{"key":"2025120519022086000_2.3.e000880.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0541-y"},{"key":"2025120519022086000_2.3.e000880.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0947-1"},{"key":"2025120519022086000_2.3.e000880.6","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2007.0215"},{"key":"2025120519022086000_2.3.e000880.7","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2005.8.876"},{"key":"2025120519022086000_2.3.e000880.8","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2010.0261"},{"key":"2025120519022086000_2.3.e000880.9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/jpm.2006.9.619","article-title":"Discontinuing lipid-lowering agents","volume":"9","author":"Davis","year":"2006","journal-title":"J Palliat Med"},{"key":"2025120519022086000_2.3.e000880.10","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2002","journal-title":"Stroke"},{"key":"2025120519022086000_2.3.e000880.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"2025120519022086000_2.3.e000880.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"2025120519022086000_2.3.e000880.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"2025120519022086000_2.3.e000880.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.5.553"},{"key":"2025120519022086000_2.3.e000880.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00045-5"},{"key":"2025120519022086000_2.3.e000880.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00820-8"},{"key":"2025120519022086000_2.3.e000880.17","unstructured":"Department of Veterans' Affairs (DVA). Annual Report 2006-2007. Canberra: DVA, 2007."},{"key":"2025120519022086000_2.3.e000880.18","unstructured":"Department of Veterans' Affairs Rehabilitation RaDG. Treatment Population Statistics. Quarterly Report September 2007. Canberra: Department of Veretans' Affairs, 2007."},{"key":"2025120519022086000_2.3.e000880.19","unstructured":"Rossi S , ed. The Australian Medicines Handbook (AMH). 12th edn. Adelaide: Australian Medicines Handbook Pty Ltd, 2011."},{"key":"2025120519022086000_2.3.e000880.20","unstructured":"Percy C Van Holten V Muir C , eds. ICD-O International Classifi Cation of Diseases for Oncology. 3rd edn. Geneva: WHO, 1990."},{"key":"2025120519022086000_2.3.e000880.21","unstructured":"AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries). Cancer in Australia: An Overview, 2008. Cancer Series No. 46. Cat No. CAN 42. Canberra: AIHW, 2008."},{"key":"2025120519022086000_2.3.e000880.22","unstructured":"Tracey E Kerr T Dobrovic A . Cancer in NSW: Incidence and Mortality Report 2008. Sydney: Cancer Institute NSW, 2010."},{"key":"2025120519022086000_2.3.e000880.23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2261-11-46","article-title":"Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study","volume":"11","author":"Latry","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"2025120519022086000_2.3.e000880.24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index: C10AA HMG CoA Reductase Inhibitors. Oslo: World Health Organization, 2011."},{"key":"2025120519022086000_2.3.e000880.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.015"},{"key":"2025120519022086000_2.3.e000880.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-6405.2009.00357.x"},{"key":"2025120519022086000_2.3.e000880.27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0290"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2012-000880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:02:29Z","timestamp":1764990149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2012-000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,5,21]]},"published-print":{"date-parts":[[2012]]}},"alternative-id":["10.1136\/bmjopen-2012-000880"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2012-000880","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}